Инновационные аспекты фармакотерапии ревматоидного артрита

Vladimir Ivanovich Petrov, Е В Черевкова, Karina S. SOLODENKOVA et al. · Вестник Волгоградского государственного медицинского университета · 2012

Up-to-date achievements in rheumatoid arthritis (RA) treatment are based on development and clinical implementation of a novel class of disease-modifying drugs which are known as biological agents. Multi-component preparations from this group contain specific monoclonal antibodies against different key molecules such as pro-inflammatory cytokines, cytokine receptors or immune cells receptors. Biological agents offer a good chance of increasing the effectiveness of RA therapy, preventing disease progression and even of controlling the process in early RA. Since biological agents can produce severe side-effects, specialists should use them with caution according to recommendations. A recent advance in the management of RA is described as well as promising investigations in this direction.

Cited by 1 works.

Authors